Literature DB >> 6356275

Rifampin: mechanisms of action and resistance.

W Wehrli.   

Abstract

Rifampin specifically inhibits bacterial RNA polymerase, the enzyme responsible for DNA transcription, by forming a stable drug-enzyme complex with a binding constant of 10(-9) M at 37 C. The corresponding mammalian enzymes are not affected by rifampin. Bacterial resistance to rifampin is caused by mutations leading to a change in the structure of the beta subunit of RNA polymerase. Such resistance is not an all-or-nothing phenomenon; rather, a large number of RNA polymerases with various degrees of sensitivity to rifampin have been found. No strict correlation exists between enzyme sensitivity and MIC values, since inhibition of RNA synthesis does not always show up to the same extent in the two different test systems used for the determination of these values.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356275     DOI: 10.1093/clinids/5.supplement_3.s407

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  82 in total

1.  Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; V Schäfer; V Brade; B Böddinghaus
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  rpoB mutation conferring rifampin resistance in Streptococcus pyogenes.

Authors:  Hélène Aubry-Damon; Marc Galimand; Guy Gerbaud; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.

Authors:  A C Keung; R C Owens; M G Eller; S J Weir; D P Nicolau; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 4.  Screening of natural products for antimicrobial agents.

Authors:  L Silver; K Bostian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

5.  Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.

Authors:  Carolina de Miranda Silva; Amirhossein Hajihosseini; Jenny Myrick; Jocelyn Nole; Arnold Louie; Stephan Schmidt; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Source-sink dynamics shape the evolution of antibiotic resistance and its pleiotropic fitness cost.

Authors:  Gabriel G Perron; Andrew Gonzalez; Angus Buckling
Journal:  Proc Biol Sci       Date:  2007-09-22       Impact factor: 5.349

7.  Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.

Authors: 
Journal:  Paediatr Child Health       Date:  2001-03       Impact factor: 2.253

8.  The rpoB gene of Mycobacterium tuberculosis.

Authors:  L P Miller; J T Crawford; T M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Ochsner J       Date:  2013

10.  Single-dose pharmacokinetics of rifapentine in elderly men.

Authors:  A C Keung; M G Eller; S J Weir
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.